OncoNano Names Brett Giroir Chief Executive
OncoNano Medicine has appointed Brett P. Giroir, its former interim CEO and board chairman, as chief executive officer.
Updated on Nov. 10, 2026 in People

OncoNano Medicine appointed Brett P. Giroir as Chief Executive Officer, announced November 10, 2026. Giroir has served as the company's Chairman of the Board and Interim CEO and has been on its board since December 2021.
Why it matters
The appointment places a former federal health official with prior leadership roles at Texas A&M in charge of OncoNano's clinical-stage cancer programs. The company's lead candidate, ONM-501, is being evaluated in a Phase 1 trial, making leadership continuity relevant to its development path.
Giroir has served on OncoNano's board since December 2021 and previously held the 16th Assistant Secretary for Health post at the U.S. Department of Health and Human Services. The extraction does not provide financial figures for the company, and the timeline for ONM-501 results remains unstated.
The players
Brett P. Giroir
Giroir is a former four-star admiral in the U.S. Public Health Service Commissioned Corps who has held senior roles at HHS, the FDA, and the Texas A&M University System.
OncoNano Medicine
OncoNano Medicine is a clinical-stage biopharmaceutical company developing cancer therapies, including its lead dual-activating STING agonist ONM-501.
The details
OncoNano, which develops cancer therapies using its ON-BOARD and OMNI platforms, named Giroir to lead the company after he served as Chairman and Interim CEO. Giroir is a former four-star admiral in the U.S. Public Health Service Commissioned Corps and previously served as Acting Commissioner of the U.S. Food and Drug Administration.
Timeline
December 2021: Giroir joined OncoNano's Board of Directors.
November 10, 2026: OncoNano announced Giroir's appointment as CEO.
Industry Dynamics
Giroir's move from acting FDA commissioner to oncology CEO illustrates how regulatory-agency leaders increasingly move into private drug developers. The shift places someone with direct knowledge of the approval process at the head of a company now advancing cancer candidates through early trials.
For Dallas-area residents tracking biotech employers, the leadership change signals continuity at OncoNano rather than a new strategic direction. The extraction does not describe any direct effect on patients, pricing, or local hiring.
The takeaway
Leadership with regulatory experience can shape how a biotech company plans its path from early trials to approval. Readers following the sector should watch how OncoNano advances ONM-501 under its new chief executive.
Further reading
Explore more People coverage to see other business leadership moves.
More information
Visit the OncoNano Medicine company website for details on its clinical programs.






